Biological and imaging characteristics and radiation dose rates associated with the use of technetium-99m-labelled imidodiphosphate in the horse.
The biological and imaging characteristics of technetium-99m imidodiphosphate (Tc99m-IDP) were measured in 4 horses once and in 1 horse twice. All computational results are expressed with 95.5% (mean +/- 2 SD) confidence limits. The clearance half-time of the radiopharmaceutical from the blood was 29.6 +/- 2.3 min. The percentage of the administered dose circulating in the whole-blood volume at 4 h was 3.9 +/- 0.8%. The Tc99m-IDP radioactivity confined at the plasma fraction of the whole blood at 4 h was 85.3 +/- 1.6%. At 8 h, approximately 45 +/- 16% of the dose administered had been excreted via the urine. The mean effective half-time of the urine activity concentration was 1.1 +/- 0.3 h. The ratios of bone-to-soft tissue activities increased with time postinjection. Urinary radioactivity concentration measurements and radiation dose rate measurements immediately behind the elbows were analysed and it was determined that 24 h is an appropriate radioisolation time for mature horses administered 3.7 GBq (100 mCi) Tc99m-IDP.
Riddolls
L J
LJ
Equine Research Centre, University of Guelph, Ontario.
Byford
G G
GG
McKee
S L
SL
D000818:Animals; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D006207:Half-Life; D006736:Horses; D008657:Metabolic Clearance Rate; D008954:Models, Biological; D009943:Organophosphorus Compounds / Q000097:blood / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000097:blood / Q000493:pharmacokinetics*; D011877:Radionuclide Imaging / Q000295:instrumentation / Q000379:methods / Q000662:veterinary; D012867:Skin
D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; C035003:technetium Tc 99m-imidodiphosphate